The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

Despite improvement of antifungal therapies over the last 30 years, the phenomenon of
antifungal resistance is still of major concern in clinical practice. In the last 10 years the …

Fungal biofilm infections have become increasingly recognised as a significant clinical
problem. One of the major reasons behind this is the impact that these have upon treatment …

The incidence of invasive mycoses is increasing, especially among patients who are
immunocompromised or hospitalized with serious underlying diseases. Such infections may …

Real-time PCR has revolutionized the way clinical microbiology laboratories diagnose many
human microbial infections. This testing method combines PCR chemistry with fluorescent …

Pathogenic fungi have become a leading cause of human mortality due to the increasing
frequency of fungal infections in immunocompromised populations and the limited …

Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has
been reported infrequently. The first resistant isolate was detected in 1999 in Manchester …

Fungi cause serious infections in the immunocompromised and debilitated, and the
incidence of invasive mycoses has increased significantly over the last 3 decades. Slow …